Weatherald J, Fleming T, Wilkins M, Cascino T, Psotka M, Zamanian R
Eur Respir J. 2024; 64(4).
PMID: 39209468
PMC: 11525337.
DOI: 10.1183/13993003.01205-2024.
Toma M, Savonitto G, Lombardi C, Airo E, Driussi M, Gentile P
Clin Res Cardiol. 2024; 114(2):215-226.
PMID: 38619580
PMC: 11839797.
DOI: 10.1007/s00392-024-02448-9.
Deshwal H, Weinstein T, Salyer R, Thompson J, Cefali F, Fenton R
Ther Adv Respir Dis. 2023; 17:17534666231199693.
PMID: 37795626
PMC: 10557422.
DOI: 10.1177/17534666231199693.
Wang M, Chi P, Cheng C, Huang W, Chen L
Cardiol J. 2023; 31(2):285-299.
PMID: 37772357
PMC: 11076026.
DOI: 10.5603/cj.92813.
Wang A, Chen M, Zhuang Q, Guan L, Xie W, Wang L
Front Cardiovasc Med. 2023; 10:1142721.
PMID: 37378404
PMC: 10291317.
DOI: 10.3389/fcvm.2023.1142721.
Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials.
Blette B, Moutchia J, Al-Naamani N, Ventetuolo C, Cheng C, Appleby D
Lancet Respir Med. 2023; 11(10):873-882.
PMID: 37230098
PMC: 10592525.
DOI: 10.1016/S2213-2600(23)00155-8.
Risk assessment validation in patients with pulmonary arterial hypertension: Data from a Southern Brazil registry (RESPHIRAR study).
Spilimbergo F, Rodrigues R, Credidio Dias-Pinto M, Blanco D, Barbieri G, Andrade-Lima M
Pulm Circ. 2023; 13(1):e12193.
PMID: 36968814
PMC: 10031811.
DOI: 10.1002/pul2.12193.
Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator.
Ahmed A, Ahmed S, Kempe D, Radegran G
Eur Heart J Open. 2023; 3(2):oead012.
PMID: 36959867
PMC: 10027577.
DOI: 10.1093/ehjopen/oead012.
Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension.
Badagliacca R, DAlto M, Ghio S, Argiento P, Brunetti N, Casu G
ERJ Open Res. 2022; 8(4).
PMID: 36382240
PMC: 9638831.
DOI: 10.1183/23120541.00298-2022.
Risk Prediction and Right Ventricular Dilation in a Single-Institution Pulmonary Arterial Hypertension Cohort.
Pi H, Carlson S, Barros L, Hogl L, Kirkpatrick J, Nolley S
J Am Heart Assoc. 2022; 11(14):e025521.
PMID: 35861845
PMC: 9707840.
DOI: 10.1161/JAHA.122.025521.
Utilization of risk assessment tools in management of PAH: A PAH provider survey.
Sahay S, Balasubramanian V, Memon H, Poms A, Bossone E, Highland K
Pulm Circ. 2022; 12(2):e12057.
PMID: 35514787
PMC: 9063963.
DOI: 10.1002/pul2.12057.
Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension.
Arevalo C, White R, Lachant D
Respir Med Case Rep. 2022; 37:101646.
PMID: 35494550
PMC: 9038566.
DOI: 10.1016/j.rmcr.2022.101646.
Lung transplantation for pulmonary hypertension.
Hwalek A, Rosenheck J, Whitson B
J Thorac Dis. 2022; 13(11):6708-6716.
PMID: 34992846
PMC: 8662488.
DOI: 10.21037/jtd-2021-20.
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension.
Frantz R, Benza R, Channick R, Chin K, Howard L, McLaughlin V
Pulm Circ. 2021; 11(4):20458940211057071.
PMID: 34790348
PMC: 8591655.
DOI: 10.1177/20458940211057071.
External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry.
Boucly A, Weatherald J, Savale L, de Groote P, Cottin V, Prevot G
Eur Respir J. 2021; 59(6).
PMID: 34737227
PMC: 9245192.
DOI: 10.1183/13993003.02419-2021.
Advances in the management of pulmonary arterial hypertension.
Deshwal H, Weinstein T, Sulica R
J Investig Med. 2021; 69(7):1270-1280.
PMID: 34580123
PMC: 8485135.
DOI: 10.1136/jim-2021-002027.
Pulmonary Arterial Remodeling Is Related to the Risk Stratification and Right Ventricular-Pulmonary Arterial Coupling in Patients With Pulmonary Arterial Hypertension.
Grignola J, Domingo E, Lopez-Meseguer M, Trujillo P, Bravo C, Perez-Hoyos S
Front Physiol. 2021; 12:631326.
PMID: 34012405
PMC: 8126681.
DOI: 10.3389/fphys.2021.631326.
Risk Stratification in Pulmonary Arterial Hypertension: Do Not Forget the Patient Perspective.
Humbert M, Lau E
Am J Respir Crit Care Med. 2020; 203(6):675-677.
PMID: 33357026
PMC: 7958524.
DOI: 10.1164/rccm.202012-4350ED.
Riociguat: Clinical research and evolving role in therapy.
Klinger J, Chakinala M, Langleben D, Rosenkranz S, Sitbon O
Br J Clin Pharmacol. 2020; 87(7):2645-2662.
PMID: 33242341
PMC: 8359233.
DOI: 10.1111/bcp.14676.
Risk assessment in patients with functional class II pulmonary arterial hypertension: Comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score.
Sahay S, Tonelli A, Selej M, Watson Z, Benza R
PLoS One. 2020; 15(11):e0241504.
PMID: 33175857
PMC: 7657501.
DOI: 10.1371/journal.pone.0241504.
